CAD 0.06
(-7.69%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.04 CAD | 67.27% |
2022 | -0.11 CAD | 50.0% |
2021 | -0.22 CAD | 54.17% |
2020 | -0.48 CAD | -5206.38% |
2019 | 0.01 CAD | 107.83% |
2018 | -0.12 CAD | 40.0% |
2017 | -0.20 CAD | -198.51% |
2016 | -0.07 CAD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.01 CAD | 28.09% |
2024 Q1 | -0.01 CAD | -20.27% |
2023 FY | - CAD | 67.27% |
2023 Q4 | -0.01 CAD | 31.48% |
2023 Q3 | -0.01 CAD | -58.82% |
2023 Q2 | -0.01 CAD | 37.61% |
2023 Q1 | -0.01 CAD | 45.23% |
2022 Q1 | -0.03 CAD | 65.75% |
2022 FY | - CAD | 50.0% |
2022 Q4 | -0.02 CAD | 32.77% |
2022 Q3 | -0.03 CAD | 1.33% |
2022 Q2 | -0.03 CAD | 0.0% |
2021 FY | - CAD | 54.17% |
2021 Q4 | -0.09 CAD | -192.0% |
2021 Q3 | -0.03 CAD | 40.0% |
2021 Q2 | -0.05 CAD | 28.57% |
2021 Q1 | -0.07 CAD | 69.57% |
2020 Q3 | -0.11 CAD | -450.0% |
2020 Q2 | -0.02 CAD | 84.62% |
2020 Q1 | -0.13 CAD | -448.52% |
2020 FY | - CAD | -5206.38% |
2020 Q4 | -0.23 CAD | -109.09% |
2019 FY | - CAD | 107.83% |
2019 Q3 | 0.03 CAD | 50.0% |
2019 Q2 | 0.02 CAD | 508.16% |
2019 Q1 | -0.00 CAD | 86.39% |
2019 Q4 | -0.02 CAD | -179.0% |
2018 Q4 | -0.04 CAD | -4400.0% |
2018 Q2 | -0.01 CAD | 96.94% |
2018 Q1 | -0.36 CAD | -8081.82% |
2018 FY | - CAD | 40.0% |
2018 Q3 | -0.00 CAD | 92.73% |
2017 FY | - CAD | -198.51% |
2017 Q3 | -0.02 CAD | -166.13% |
2017 Q2 | -0.01 CAD | 85.94% |
2017 Q1 | -0.04 CAD | 0.0% |
2017 Q4 | -0.00 CAD | 73.33% |
2016 FY | - CAD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Aurora Cannabis Inc. | -1.60 CAD | 97.75% |
Avicanna Inc. | -0.09 CAD | 61.332% |
Avant Brands Inc. | -0.61 CAD | 94.098% |
Cardiol Therapeutics Inc. | -0.44 CAD | 91.818% |
Crescita Therapeutics Inc. | -0.10 CAD | 63.265% |
Knight Therapeutics Inc. | -0.16 CAD | 77.5% |
OrganiGram Holdings Inc. | -2.82 CAD | 98.723% |
Canopy Growth Corporation | -8.79 CAD | 99.59% |
Willow Biosciences Inc. | -0.10 CAD | 64.0% |
Auxly Cannabis Group Inc. | -0.04 CAD | 19.822% |